Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-derived Pleiotropic Factor for Chronic Wounds
NCT04235868Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2019
- Primary completion
- Aug 2020
- Modality
- Cytokines & Interferons, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of mesenchymal stem cell-derived pleiotropic factor in Chronic wound (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Wound healing rate at 1 month. Status: unknown.
02
Drugs
mesenchymal stem cell-derived pleiotropic factor
03
Conditions
Chronic wound
Beyond the preview
Go deeper on NCT04235868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235868.